Pfizer announced last week that it is discontinuing development of its twice-daily weight loss pill "danuglipron" after a clinical trial showed "high rates" of adverse side effects among users.
The U.S. Food and Drug Administration (FDA) is investigating the cancer treatment CAR-T after it was notified of new blood cancers among individuals who received the treatment.